Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Scotiabank analyst George Farmer maintained a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

On Friday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $49.27 which represents a slight increase of $2.42 or 5.17% from the prior close of $46.85. The stock opened at ...

Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.94% of ...

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.

More details are emerging about the Parkinson's disease diagnosis Brett Favre revealed before Congress this week. The Green ...